Prosecution Insights
Last updated: November 04, 2026

Chryos LLC

Technology area: Biotechnology & Pharmaceuticals

1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready

Analysis

Chryos LLC focuses on the Biotechnology & Pharmaceuticals technology area. The company has 1 pending office action currently active. This action is assigned to 1 distinct examiner and 1 distinct art unit.

FOX, ALLISON M is the busiest examiner for this portfolio, managing 1 pending office action. This single figure represents the total pending workload for the company. The prosecution environment is highly centralized with no variation in examiners or units. This arrangement allows for a highly focused legal strategy.

The presence of 1 pending office action indicates a low volume of active disputes. Because only 1 distinct examiner is involved, the company's prosecution efforts are focused on a single relationship. Practitioners should analyze the specific requirements of FOX, ALLISON M to address the 1 pending action. The 1 distinct art unit suggests a specific technical focus for the pending application.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

1
Total Pending OAs
1
Non-Final OAs
0
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
1
Medium (100%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
Double-patenting + other1 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

1
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

10 h
Manual time on pending OAs
2 h
Time saved (low, 20%)
4 h
Time saved (mid, 35%)
0.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
FOX, ALLISON M 1 71.0% +35.7%

Interview Candidates (1)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18542272 COMPOSITION AND METHOD OF USE OF THE SAME FOR PRESERVING CELLS FOR ANALYSIS FOX, ALLISON M —

Top Art Units

Art UnitApps
1633 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18542272 COMPOSITION AND METHOD OF USE OF THE SAME FOR PRESERVING CELLS FOR ANALYSIS FOX, ALLISON M 1633 §103§112DP Non-Final OA — Pending Dec 15, 2023

Managing Chryos LLC's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Chryos LLC have?

Chryos LLC has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.

Which USPTO examiner handles the most Chryos LLC applications?

Allison M Fox has the most, with 1 of Chryos LLC's pending office actions.

What technology area are Chryos LLC's patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month